Intuitive Surgical Inc
$ 494.02
0.39%
24 Feb - close price
- Market Cap 174,759,592,000 USD
- Current Price $ 494.02
- High / Low $ 496.27 / 487.51
- Stock P/E 62.53
- Book Value 50.19
- EPS 7.87
- Next Earning Report 2026-04-21
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.09 %
- ROE 0.17 %
- 52 Week High 603.88
- 52 Week Low 425.00
About
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.
Analyst Target Price
$610.79
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-01-22 | 2025-10-16 | 2025-07-22 | 2025-04-22 | 2025-01-23 | 2024-10-17 | 2024-07-18 | 2024-04-18 | 2024-01-23 | 2023-10-19 | 2023-07-20 | 2023-04-18 |
| Reported EPS | 2.53 | 2.4 | 2.19 | 1.81 | 2.21 | 1.84 | 1.78 | 1.5 | 1.6 | 1.46 | 1.42 | 1.23 |
| Estimated EPS | 2.26 | 1.99 | 1.92 | 1.73 | 1.79 | 1.64 | 1.54 | 1.41 | 1.48 | 1.41 | 1.33 | 1.2 |
| Surprise | 0.27 | 0.41 | 0.27 | 0.08 | 0.42 | 0.2 | 0.24 | 0.09 | 0.12 | 0.05 | 0.09 | 0.03 |
| Surprise Percentage | 11.9469% | 20.603% | 14.0625% | 4.6243% | 23.4637% | 12.1951% | 15.5844% | 6.383% | 8.1081% | 3.5461% | 6.7669% | 2.5% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-21 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | 2.13 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ISRG
2026-02-24 21:50:34
Medtronic (MDT) reported mixed Q3 FY26 results with higher sales but lower net income and reaffirmed its full-year EPS guidance. The company is navigating margin pressures, a $381 million antitrust verdict, and the restructuring of its diabetes business, including a planned spin-off. These factors are central to its investment narrative, balancing diversification and dividend history against ongoing operational challenges.
2026-02-24 19:48:29
UBS has lowered its price target for Intuitive Surgical (ISRG) from $600.00 to $570.00, a 5% decrease, while maintaining a Neutral rating. This adjustment is part of a series of analyst actions, though many other firms have recently increased their price targets and maintained optimistic ratings for the company. Wall Street analysts currently forecast an average target price of $612.26 for ISRG, suggesting a 23.46% upside from its current price, with a consensus brokerage recommendation of "Outperform."
2026-02-24 17:40:00
BD has launched the BD Vacutainer Urine Complete Cup Kit, a three-tube collection system aimed at improving diagnostic accuracy and laboratory efficiency by enabling expanded testing from a single specimen. This new kit is designed to maintain specimen integrity, reduce contamination risks, and streamline workflows, addressing a critical source of diagnostic error in preanalytical processes. The company anticipates this innovation will strengthen its position in the urinalysis market and contribute to revenue growth, with its stock price performance being observed closely.
2026-02-24 14:50:35
The Zacks Analyst Blog features research reports on Oracle, Intuitive Surgical, Analog Devices, and Moving iMage Technologies, offering insights into their recent performance and market outlook. Oracle faces competition and transition risks but shows cloud growth, while Intuitive Surgical demonstrates strong da Vinci 5 system placements and procedure growth despite margin pressure. Analog Devices benefits from broad recovery and secular growth drivers, and Moving iMage Technologies shows signs of earnings inflection despite liquidity concerns.
2026-02-24 13:50:27
Henry Schein, Inc. (HSIC) reported strong fourth-quarter 2025 results, with adjusted EPS of $1.34 and net sales of $3.44 billion, both surpassing Zacks Consensus Estimates. The company experienced significant sales growth across its Dental, Medical, Specialty Products, and Technology segments. Despite revenue beats, both gross and operating margins contracted, attributed to increased cost of sales and SG&A expenses.
2026-02-24 13:50:15
Zacks Equity Research highlights Intuitive Surgical, Edwards Lifesciences, and Electromed as key players in the Medical Instruments industry, emphasizing the growing impact of Generative AI (GenAI) on diagnostics, patient monitoring, and intervention workflows. The article discusses how GenAI and M&A trends are shaping the future of the industry, despite economic pressures and regulatory adaptations. It provides a positive outlook for these three companies, citing strong earnings growth estimates and their adaptability to market changes.
